These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

300 related items for PubMed ID: 17097412

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Clopidogrel added to aspirin versus aspirin alone in secondary prevention and high-risk primary prevention: rationale and design of the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) trial.
    Bhatt DL, Topol EJ, Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance Executive Committee.
    Am Heart J; 2004 Aug; 148(2):263-8. PubMed ID: 15308995
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Combination antiplatelet agents for secondary prevention of ischemic stroke.
    Vande Griend JP, Saseen JJ.
    Pharmacotherapy; 2008 Oct; 28(10):1233-42. PubMed ID: 18823219
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Indications for dual antiplatelet therapy with aspirin and clopidogrel: evidence-based recommendations for use.
    Reaume KT, Regal RE, Dorsch MP.
    Ann Pharmacother; 2008 Apr; 42(4):550-7. PubMed ID: 18319394
    [Abstract] [Full Text] [Related]

  • 10. Clopidogrel resistance?
    Gurbel PA, Tantry US.
    Thromb Res; 2007 Apr; 120(3):311-21. PubMed ID: 17109936
    [Abstract] [Full Text] [Related]

  • 11. Bleeding complications with dual antiplatelet therapy among patients with stable vascular disease or risk factors for vascular disease: results from the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) trial.
    Berger PB, Bhatt DL, Fuster V, Steg PG, Fox KA, Shao M, Brennan DM, Hacke W, Montalescot G, Steinhubl SR, Topol EJ, CHARISMA Investigators.
    Circulation; 2010 Jun 15; 121(23):2575-83. PubMed ID: 20516378
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Safety and tolerability of antiplatelet therapies for the secondary prevention of atherothrombotic disease.
    Spinler SA.
    Pharmacotherapy; 2009 Jul 15; 29(7):812-21. PubMed ID: 19558255
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Combination antiplatelet therapy in patients with peripheral arterial disease: is the best therapy aspirin, clopidogrel, or both?
    Mohler ER.
    Catheter Cardiovasc Interv; 2009 Jul 01; 74 Suppl 1():S1-6. PubMed ID: 19213065
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. An analysis of mortality rates with dual-antiplatelet therapy in the primary prevention population of the CHARISMA trial.
    Wang TH, Bhatt DL, Fox KA, Steinhubl SR, Brennan DM, Hacke W, Mak KH, Pearson TA, Boden WE, Steg PG, Flather MD, Montalescot G, Topol EJ, CHARISMA Investigators.
    Eur Heart J; 2007 Sep 01; 28(18):2200-7. PubMed ID: 17673448
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.